Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2015 1
2016 4
2017 2
2018 3
2020 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD.
Wingerchuk DM, Fujihara K, Palace J, Berthele A, Levy M, Kim HJ, Nakashima I, Oreja-Guevara C, Wang KC, Miller L, Shang S, Sabatella G, Yountz M, Pittock SJ; PREVENT Study Group. Wingerchuk DM, et al. Ann Neurol. 2021 Jun;89(6):1088-1098. doi: 10.1002/ana.26049. Epub 2021 Feb 27. Ann Neurol. 2021. PMID: 33586143 Free PMC article. Clinical Trial.
Fibroblast growth factor-23 (FGF-23) / soluble Klotho protein (sKlotho) / sclerostin glycoprotein ratio disturbance is a novel risk factor for cardiovascular complications in ESRD patients receiving treatment with regular hemodialysis or hemodiafiltration.
Milovanova LY, Dobrosmyslov IA, Milovanov YS, Taranova MV, Kozlov VV, Milovanova SY, Kozevnikova EI. Milovanova LY, et al. Among authors: milovanov ys. Ter Arkh. 2018 Jun 20;90(6):48-54. doi: 10.26442/terarkh201890648-54. Ter Arkh. 2018. PMID: 30701904
Effect of essential amino acid кetoanalogues and protein restriction diet on morphogenetic proteins (FGF-23 and Кlotho) in 3b-4 stages chronic кidney disease patients: a randomized pilot study.
Milovanova L, Fomin V, Moiseev S, Taranova M, Milovanov Y, Lysenko Kozlovskaya L, Kozlov V, Kozevnikova E, Milovanova S, Lebedeva M, Reshetnikov V. Milovanova L, et al. Among authors: milovanov y. Clin Exp Nephrol. 2018 Dec;22(6):1351-1359. doi: 10.1007/s10157-018-1591-1. Epub 2018 Jun 11. Clin Exp Nephrol. 2018. PMID: 29948444 Clinical Trial.
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; TREAT Investigators. Pfeffer MA, et al. N Engl J Med. 2009 Nov 19;361(21):2019-32. doi: 10.1056/NEJMoa0907845. Epub 2009 Oct 30. N Engl J Med. 2009. PMID: 19880844 Free article. Clinical Trial.
[Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease].
Milovanova LY, Milovanov YS, Kudryavtseva DV, Markina MM, Milovanova SY, Kozlovskaya LV, Lebedeva MV, Beketov VD, Moiseev SV, Mukhin NA, Fomin VV, Svistunov AA. Milovanova LY, et al. Among authors: milovanov ys. Ter Arkh. 2015;87(6):10-16. doi: 10.17116/terarkh201587610-16. Ter Arkh. 2015. PMID: 26281189 Russian.
13 results